MX2019009367A - Grupos linfoides asociados al tejido graso como sitios de trasplante, regeneración de tejidos, organogénesis y función para múltiples tejidos. - Google Patents
Grupos linfoides asociados al tejido graso como sitios de trasplante, regeneración de tejidos, organogénesis y función para múltiples tejidos.Info
- Publication number
- MX2019009367A MX2019009367A MX2019009367A MX2019009367A MX2019009367A MX 2019009367 A MX2019009367 A MX 2019009367A MX 2019009367 A MX2019009367 A MX 2019009367A MX 2019009367 A MX2019009367 A MX 2019009367A MX 2019009367 A MX2019009367 A MX 2019009367A
- Authority
- MX
- Mexico
- Prior art keywords
- tissue
- falc
- ectopic
- compositions
- organogenesis
- Prior art date
Links
- 210000000577 adipose tissue Anatomy 0.000 title abstract 2
- 230000005305 organ development Effects 0.000 title 1
- 210000001519 tissue Anatomy 0.000 title 1
- 230000017423 tissue regeneration Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 210000005228 liver tissue Anatomy 0.000 abstract 2
- 239000008267 milk Substances 0.000 abstract 2
- 210000004080 milk Anatomy 0.000 abstract 2
- 235000013336 milk Nutrition 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 208000016216 Choristoma Diseases 0.000 abstract 1
- 206010063044 Ectopic kidney Diseases 0.000 abstract 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 abstract 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 abstract 1
- 102000003945 NF-kappa B Human genes 0.000 abstract 1
- 108010057466 NF-kappa B Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 210000005084 renal tissue Anatomy 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
Abstract
La presente descripción se refiere al injerto y la proliferación de células en grupos linfoides asociados al tejido graso ("FALC" o "manchas de leche") , que pueden usarse para generar tejido ectópico funcional. La presente descripción proporciona además métodos y composiciones para injertar u proliferar células, en FALC activando el receptor de linfotoxina beta (LTßR) y/o la vía de señalización de la quinasa inductora de NF-kB (NIK). La presente descripción también proporciona métodos y composiciones para establecer tejido hepático ectópico en FALC (manchas de leche) y usar dicho tejido hepático ectópico para beneficio terapéutico, y proporcionar métodos y composiciones para generar tejido renal ectópico en FALC, que pueden usarse en un paciente para un beneficio terapéutico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762460267P | 2017-02-17 | 2017-02-17 | |
| US201762574119P | 2017-10-18 | 2017-10-18 | |
| PCT/US2018/018684 WO2018152488A1 (en) | 2017-02-17 | 2018-02-20 | Fat-associated lymphoid clusters as sites for transplantation,tissue regeneration, organogenesis and function for multiple tissues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019009367A true MX2019009367A (es) | 2019-10-24 |
Family
ID=63170490
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009367A MX2019009367A (es) | 2017-02-17 | 2018-02-20 | Grupos linfoides asociados al tejido graso como sitios de trasplante, regeneración de tejidos, organogénesis y función para múltiples tejidos. |
| MX2024005097A MX2024005097A (es) | 2017-02-17 | 2019-08-06 | Grupos linfoides asociados al tejido graso como sitios de trasplante, regeneracion de tejidos, organogenesis y funcion para multiples tejidos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005097A MX2024005097A (es) | 2017-02-17 | 2019-08-06 | Grupos linfoides asociados al tejido graso como sitios de trasplante, regeneracion de tejidos, organogenesis y funcion para multiples tejidos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190374583A1 (es) |
| EP (1) | EP3582794A4 (es) |
| JP (3) | JP2020508298A (es) |
| KR (2) | KR20250020727A (es) |
| CN (2) | CN119097642A (es) |
| AU (1) | AU2018221254B2 (es) |
| BR (1) | BR112019016965A2 (es) |
| CA (1) | CA3052295A1 (es) |
| IL (2) | IL268389B2 (es) |
| MX (2) | MX2019009367A (es) |
| WO (1) | WO2018152488A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2600256B (en) * | 2019-04-11 | 2024-02-21 | Univ Pittsburgh Commonwealth Sys Higher Education | Minimally invasive cell transplant procedure to induce the development of in vivo organogenesis |
| WO2023076279A1 (en) * | 2021-10-25 | 2023-05-04 | Satellite Biosciences, Inc. | Engineered tissue constructs for the treatment of crigler-najjar syndrome |
| CN116925997B (zh) * | 2023-07-27 | 2024-04-02 | 湖北医药学院 | 左氧氟沙星在制备促进细胞增殖中的药物的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6312691B1 (en) | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
| CN101974480A (zh) | 2001-06-22 | 2011-02-16 | 干细胞股份有限公司 | 肝移植细胞、测定及其应用 |
| WO2009111778A2 (en) * | 2008-03-07 | 2009-09-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Lymph nodes as a site for regeneration |
| WO2014138486A1 (en) * | 2013-03-06 | 2014-09-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Lymph node as a site for transplantation, organogenesis and function for multiple tissues and organs |
| US11191785B2 (en) * | 2008-03-07 | 2021-12-07 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Lymph node as a site for transplantation, organogenesis and function for multiple tissues and organs |
| JP2015501839A (ja) * | 2011-12-15 | 2015-01-19 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 受容体に対する親和性が増大した変異型ｌｉｇｈｔ分子を使用する癌療法のための方法および組成物 |
-
2018
- 2018-02-20 CN CN202411079982.8A patent/CN119097642A/zh active Pending
- 2018-02-20 MX MX2019009367A patent/MX2019009367A/es unknown
- 2018-02-20 EP EP18754087.7A patent/EP3582794A4/en active Pending
- 2018-02-20 AU AU2018221254A patent/AU2018221254B2/en active Active
- 2018-02-20 KR KR1020257002956A patent/KR20250020727A/ko active Pending
- 2018-02-20 CA CA3052295A patent/CA3052295A1/en active Pending
- 2018-02-20 IL IL268389A patent/IL268389B2/en unknown
- 2018-02-20 CN CN201880025487.5A patent/CN110869032B/zh active Active
- 2018-02-20 IL IL310219A patent/IL310219A/en unknown
- 2018-02-20 WO PCT/US2018/018684 patent/WO2018152488A1/en not_active Ceased
- 2018-02-20 KR KR1020197027026A patent/KR102762505B1/ko active Active
- 2018-02-20 JP JP2019543979A patent/JP2020508298A/ja active Pending
- 2018-02-20 BR BR112019016965A patent/BR112019016965A2/pt unknown
-
2019
- 2019-08-06 MX MX2024005097A patent/MX2024005097A/es unknown
- 2019-08-16 US US16/542,490 patent/US20190374583A1/en not_active Abandoned
-
2023
- 2023-01-26 JP JP2023010078A patent/JP7784392B2/ja active Active
- 2023-08-23 US US18/454,646 patent/US20240091271A1/en active Pending
-
2025
- 2025-08-01 JP JP2025129210A patent/JP2025176014A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3582794A1 (en) | 2019-12-25 |
| JP7784392B2 (ja) | 2025-12-11 |
| US20240091271A1 (en) | 2024-03-21 |
| WO2018152488A1 (en) | 2018-08-23 |
| IL310219A (en) | 2024-03-01 |
| KR102762505B1 (ko) | 2025-02-03 |
| AU2018221254B2 (en) | 2025-03-20 |
| CN110869032A (zh) | 2020-03-06 |
| IL268389B2 (en) | 2024-06-01 |
| BR112019016965A2 (pt) | 2020-04-14 |
| CA3052295A1 (en) | 2018-08-23 |
| JP2023061960A (ja) | 2023-05-02 |
| CN119097642A (zh) | 2024-12-10 |
| KR20250020727A (ko) | 2025-02-11 |
| KR20190116439A (ko) | 2019-10-14 |
| CN110869032B (zh) | 2024-08-23 |
| EP3582794A4 (en) | 2020-12-09 |
| IL268389A (en) | 2019-09-26 |
| IL268389B1 (en) | 2024-02-01 |
| MX2024005097A (es) | 2024-05-15 |
| JP2025176014A (ja) | 2025-12-03 |
| AU2018221254A1 (en) | 2019-08-15 |
| JP2020508298A (ja) | 2020-03-19 |
| US20190374583A1 (en) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
| ECSP12011908A (es) | OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO | |
| AR120223A1 (es) | Proteínas que unen nkg2d, cd16 y flt3 | |
| ECSP20077518A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| ECSP20018487A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| MX2016016236A (es) | Anticuerpos dirigidos contra cd127. | |
| MX2024005097A (es) | Grupos linfoides asociados al tejido graso como sitios de trasplante, regeneracion de tejidos, organogenesis y funcion para multiples tejidos. | |
| ECSP12011720A (es) | Compuestos heterocíclicos y usos de los mismos | |
| MX2015011448A (es) | Compuestos y sus usos para modular la hemoglobina. | |
| CL2015002123A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
| UY32880A (es) | Nuevos derivados de tiaziazol | |
| CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
| MX378131B (es) | Compuestos y sus usos para modular la hemoglobina. | |
| UY35425A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
| GT201400222A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| UY35426A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| SV2011003830A (es) | Daa-piridina como ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes y para el tratamiento farmaceutico | |
| CR8992A (es) | Analogos de biaril piperazinilpiridina sustituida | |
| MX2020008107A (es) | Moduladores del receptor nmda espiro-lactama y usos de los mismos. | |
| CO2017006032A2 (es) | Métodos para tratar la calcificación de tejidos | |
| MX2021003110A (es) | Agonistas del receptor x farnesoide y usos de los mismos. | |
| DOP2021000251A (es) | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b | |
| PE20190502A1 (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos | |
| UY36274A (es) | Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g |